Kailera Therapeutics (NASDAQ:KLRA) Trading Down 8.6% – Should You Sell?

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA) were down 8.6% on Friday . The stock traded as low as $16.81 and last traded at $16.93. Approximately 300,058 shares were traded during mid-day trading, a decline of 58% from the average session volume of 718,964 shares. The stock had previously closed at $18.53.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on KLRA shares. Wall Street Zen cut Kailera Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Weiss Ratings started coverage on Kailera Therapeutics in a research report on Friday, August 14th. They issued a “sell (d)” rating for the company. Zacks Research upgraded shares of Kailera Therapeutics to a “hold” rating in a research note on Wednesday, May 13th. William Blair began coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They set an “outperform” rating on the stock. Finally, Jefferies Financial Group initiated coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They issued a “buy” rating and a $48.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Kailera Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $42.75.

Kailera Therapeutics Stock Down 8.6%

The company has a market cap of $2.19 billion and a price-to-earnings ratio of -0.00. The business’s 50 day simple moving average is $19.16.

Kailera Therapeutics (NASDAQ:KLRA) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.35). On average, equities research analysts expect that Kailera Therapeutics, Inc. will post -3.89 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. California State Teachers Retirement System bought a new stake in shares of Kailera Therapeutics during the 2nd quarter valued at about $309,000. Frazier Life Sciences Management L.P. bought a new position in shares of Kailera Therapeutics in the 2nd quarter worth approximately $24,233,000. Wellington Management Group LLP bought a new position in shares of Kailera Therapeutics in the 2nd quarter worth approximately $64,308,000. Finally, Atlas Venture Life Science Advisors LLC purchased a new position in shares of Kailera Therapeutics in the second quarter worth approximately $113,923,000.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.